pioglitazone has been researched along with Diabetic Glomerulosclerosis in 62 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of pioglitazone and RAS-Is showed therapeutic benefit in the reduction of urinary albumin excretion for type 2 diabetic patients with hypertension and microalbuminuria." | 9.15 | Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. ( Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H, 2011) |
| " In this study, we evaluated the clinical efficacy of pioglitazone in the treatment of diabetic patients with hypertension undergoing hemodialysis (HD)." | 9.13 | Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. ( Abe, M; Kikuchi, F; Matsumoto, K; Okada, K, 2008) |
| "Sarpogrelate has been shown to reduce albuminuria in diabetic nephropathy." | 9.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| "Pioglitazone is a newly developed antidiabetic agent that attenuates insulin resistance." | 6.70 | Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. ( Hara, M; Koide, H; Nakamura, T; Osada, S; Shimada, N; Ushiyama, C, 2001) |
| " Pioglitazone improves insulin sensitivity and it may have potential for treating CKD-related FGF23 overactivity." | 5.69 | Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial. ( Nata, N; Satirapoj, B; Supasyndh, O; Triwatana, W, 2023) |
| "Diabetic nephropathy was induced by subtotal nephrectomy plus streptozotocin (STZ) injection." | 5.38 | Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| " Long-term administration of pioglitazone improved hyperglycemia lipid profiles, hypercholesterolemia, and hyperinsulinemia and had a protective effect on diabetic nephropathy in Zucker-fatty rats." | 5.35 | Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction. ( Hirasawa, Y; Ito, M; Kawasaki, Y; Kyuki, K; Matsui, Y; Nagamatsu, T; Sakai, T; Toyoshi, T; Yabuki, SY; Yamane, K, 2008) |
| "The combination of pioglitazone and RAS-Is showed therapeutic benefit in the reduction of urinary albumin excretion for type 2 diabetic patients with hypertension and microalbuminuria." | 5.15 | Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. ( Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H, 2011) |
| " In this study, we evaluated the clinical efficacy of pioglitazone in the treatment of diabetic patients with hypertension undergoing hemodialysis (HD)." | 5.13 | Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. ( Abe, M; Kikuchi, F; Matsumoto, K; Okada, K, 2008) |
| "Sarpogrelate has been shown to reduce albuminuria in diabetic nephropathy." | 5.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| "Besides the effectiveness in blood sugar control, pioglitazone could salutarily reduce proteinuria and synthesis of TGF-beta as well as type IV collagen." | 5.12 | Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. ( Eiam-Ong, S; Katavetin, P; Suwanwalaikorn, S, 2006) |
| "The goal of the meta-analysis was to evaluate the effect of pioglitazone on the primary and secondary prevention of cardiovascular diseases (CVDs) and renal adverse events in patients with or at high risk of type 2 diabetes mellitus (T2DM)." | 5.05 | Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. ( Huang, Y; Ji, X; Shen, L; Wang, X; Wang, Y; Zhou, Y, 2020) |
| "Our findings suggested that aliskiren enhanced the protective effects of pioglitazone against myocardial fibrosis, in experimental diabetic nephropathy." | 3.78 | Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| "Treatment of OLETF rats with pioglitazone improved insulin sensitivity and kidney/body weight, but had a little effect on blood pressure." | 3.74 | Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. ( Cha, DR; Han, JY; Han, KH; Han, SY; Kang, YS; Kim, HK; Ko, GJ; Lee, MH; Song, HK, 2008) |
| "A total of 75 patients with type 2 diabetes and CKD and inadequate glycemic control receiving any pharmacological antidiabetic treatment were randomly assigned to 2 groups." | 2.87 | Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial. ( Satirapoj, B; Supasyndh, O; Watanakijthavonkul, K, 2018) |
| "Glucose-lowering treatment options for type 2 diabetes mellitus patients with chronic kidney disease are limited." | 2.80 | Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. ( Crowe, S; McGill, JB; von Eynatten, M; Woerle, HJ; Yki-Järvinen, H, 2015) |
| "Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality." | 2.79 | Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. ( Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D, 2014) |
| "Pioglitazone has advantage over rosiglitazone in lowering lipid and proinflammatory cytokines." | 2.74 | Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. ( Kumar, H; Mishra, M; Tripathi, K; Vijay, SK, 2009) |
| "In nephrotic men with diabetic nephropathy, the coefficient of variation in the month-to-month protein excretion rate is 36%." | 2.73 | Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications. ( Agarwal, R, 2007) |
| "Sixty patients with type 2 diabetic nephropathy (stage 3 or 4 chronic kidney disease) were enrolled in a randomized, controlled trial." | 2.73 | Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "In patients with advanced diabetic nephropathy, we found no reduction in proteinuria over 4 months." | 2.71 | A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. ( Agarwal, R; Battiwala, M; Chase, SD; Curley, T; Sachs, N; Saha, C; Semret, MH; Vasavada, N, 2005) |
| "Pioglitazone is a newly developed antidiabetic agent that attenuates insulin resistance." | 2.70 | Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. ( Hara, M; Koide, H; Nakamura, T; Osada, S; Shimada, N; Ushiyama, C, 2001) |
| "Thus, diabetic nephropathy is currently the number one cause of end-stage renal disease in the Western world." | 2.43 | Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. ( Bakris, GL; Sarafidis, PA, 2006) |
| "Pioglitazone has a good safety profile in diabetic patients with impaired renal function." | 2.42 | Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. ( Budde, K; Diekmann, F; Einecke, G; Fritsche, L; Glander, P; Neumayer, HH; Schötschel, R, 2003) |
| "The study aims to investigate the effect of vitamin D (VD) combined with pioglitazone hydrochloride (PIO) on bone mineral density (BMD) and bone metabolism in patients with Type 2 diabetic nephropathy (T2DN)." | 1.46 | Effects of vitamin D combined with pioglitazone hydrochloride on bone mineral density and bone metabolism in Type 2 diabetic nephropathy. ( Dong, L; Li, BL; Wang, LX; Wang, N; Xu, QL; Yan, W, 2017) |
| " All animals were dosed with 1 mg/kg of hIgG intravenously (IV) or subcutaneously (SC)." | 1.42 | Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. ( Chadha, GS; Morris, ME, 2015) |
| "Pioglitazone treatment incompletely reversed the disease-related PK changes." | 1.42 | An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats. ( Chadha, GS; Morris, ME, 2015) |
| "Diabetic nephropathy was induced by subtotal nephrectomy plus streptozotocin (STZ) injection." | 1.38 | Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| "Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in diabetic rats." | 1.38 | Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. ( Hu, W; Liu, D; Yu, Q; Zhang, J, 2012) |
| "Diabetic nephropathy is a serious diabetic complication that leads to end stage renal disease." | 1.38 | Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats. ( Abd El-All, HS; Ewais, MM; Masoad, RE; Tawfik, MK, 2012) |
| "Telmisartan treatment is equieffective as pioglitazone in attenuating acute I/R-induced renal injury in diabetic rats by a modification in the oxidative stress and the inflammation." | 1.38 | Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats. ( Tawfik, MK, 2012) |
| " Long-term administration of pioglitazone improved hyperglycemia lipid profiles, hypercholesterolemia, and hyperinsulinemia and had a protective effect on diabetic nephropathy in Zucker-fatty rats." | 1.35 | Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction. ( Hirasawa, Y; Ito, M; Kawasaki, Y; Kyuki, K; Matsui, Y; Nagamatsu, T; Sakai, T; Toyoshi, T; Yabuki, SY; Yamane, K, 2008) |
| "Pioglitazone was effective in the treatment of diabetics on dialysis therapy." | 1.35 | Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis. ( Abe, M; Kaizu, K; Kikuchi, F; Matsumoto, K; Okada, K, 2008) |
| "Diabetic nephropathy is the most serious of complications in diabetes mellitus." | 1.34 | Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. ( Cho, BP; Chung, CH; Koh, JH; Lee, BJ; Lee, EY; Lee, MY; Shin, JY; Shin, YG; Won, CS, 2007) |
| "Hyperinsulinemia has been implicated in the development of diabetic nephropathy." | 1.34 | Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. ( Izuhara, Y; Kakuta, T; Miyata, T; Ohtomo, S; Takizawa, S; van Ypersele de Strihou, C; Yamada, N, 2007) |
| "Patients with diabetic nephropathy have a high rate of cardiovascular events and mortality." | 1.33 | Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. ( Agarwal, R, 2006) |
| "These effects in the early stage of diabetic nephropathy have not been fully described." | 1.32 | Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. ( Fan, Q; Gohda, T; Makita, Y; Shike, T; Tanimoto, M; Tomino, Y, 2004) |
| "Diabetic nephropathy is characterized functionally by glomerular hyperfiltration and albuminuria and histologically by the expansion of glomerular mesangium." | 1.31 | Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. ( Haneda, M; Kikkawa, R; Koya, D, 2001) |
| "Treatment with pioglitazone significantly improved glucose and lipid metabolism." | 1.30 | Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. ( Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.61) | 18.2507 |
| 2000's | 28 (45.16) | 29.6817 |
| 2010's | 29 (46.77) | 24.3611 |
| 2020's | 4 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, CC | 1 |
| Yang, YS | 1 |
| Huang, CN | 1 |
| Lo, SC | 1 |
| Wang, YH | 1 |
| Kornelius, E | 1 |
| Triwatana, W | 3 |
| Satirapoj, B | 4 |
| Supasyndh, O | 4 |
| Nata, N | 3 |
| Zhou, Y | 1 |
| Huang, Y | 1 |
| Ji, X | 1 |
| Wang, X | 1 |
| Shen, L | 1 |
| Wang, Y | 3 |
| Yen, CL | 1 |
| Wu, CY | 1 |
| See, LC | 1 |
| Li, YJ | 1 |
| Tseng, MH | 1 |
| Peng, WS | 1 |
| Liu, JR | 1 |
| Chen, YC | 1 |
| Yen, TH | 1 |
| Tian, YC | 1 |
| Yang, CW | 1 |
| Anderson, GF | 1 |
| Yang, HY | 1 |
| Chang, YH | 1 |
| Hwu, DW | 1 |
| Chang, DM | 1 |
| An, LW | 1 |
| Hsieh, CH | 1 |
| Lee, YJ | 1 |
| Hirano, T | 1 |
| Watanakijthavonkul, K | 1 |
| Asakura, J | 1 |
| Hasegawa, H | 1 |
| Takayanagi, K | 1 |
| Shimazu, T | 1 |
| Suge, R | 1 |
| Shimizu, T | 1 |
| Iwashita, T | 1 |
| Tayama, Y | 1 |
| Matsuda, A | 1 |
| Kanozawa, K | 1 |
| Araki, N | 1 |
| Mitarai, T | 1 |
| Ruilope, L | 1 |
| Hanefeld, M | 1 |
| Lincoff, AM | 1 |
| Viberti, G | 1 |
| Meyer-Reigner, S | 1 |
| Mudie, N | 1 |
| Wieczorek Kirk, D | 1 |
| Malmberg, K | 1 |
| Herz, M | 1 |
| Chadha, GS | 2 |
| Morris, ME | 2 |
| McGill, JB | 1 |
| Yki-Järvinen, H | 1 |
| Crowe, S | 1 |
| Woerle, HJ | 1 |
| von Eynatten, M | 1 |
| Yokoyama, H | 2 |
| Araki, S | 1 |
| Kawai, K | 1 |
| Hirao, K | 1 |
| Oishi, M | 1 |
| Sugimoto, K | 1 |
| Sone, H | 1 |
| Maegawa, H | 1 |
| Kashiwagi, A | 1 |
| Oei, E | 1 |
| Samad, N | 1 |
| Visser, A | 1 |
| Chowdhury, TA | 1 |
| Fan, SL | 1 |
| Wang, LX | 1 |
| Wang, N | 1 |
| Xu, QL | 1 |
| Yan, W | 1 |
| Dong, L | 1 |
| Li, BL | 1 |
| Hinder, LM | 1 |
| Park, M | 1 |
| Rumora, AE | 1 |
| Hur, J | 1 |
| Eichinger, F | 1 |
| Pennathur, S | 1 |
| Kretzler, M | 1 |
| Brosius, FC | 1 |
| Feldman, EL | 1 |
| Vijay, SK | 1 |
| Mishra, M | 1 |
| Kumar, H | 1 |
| Tripathi, K | 1 |
| Abe, M | 2 |
| Okada, K | 2 |
| Kikuchi, F | 2 |
| Matsumoto, K | 2 |
| Hirasawa, Y | 1 |
| Matsui, Y | 1 |
| Yamane, K | 1 |
| Yabuki, SY | 1 |
| Kawasaki, Y | 1 |
| Toyoshi, T | 1 |
| Kyuki, K | 1 |
| Ito, M | 1 |
| Sakai, T | 1 |
| Nagamatsu, T | 1 |
| Miyata, T | 2 |
| van Ypersele de Strihou, C | 2 |
| Lambley, RG | 1 |
| Vahdani, K | 2 |
| Konstantinidis, A | 1 |
| Booth, A | 1 |
| Fukuda, M | 1 |
| Nakamura, T | 3 |
| Kataoka, K | 1 |
| Nako, H | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Sarafidis, PA | 2 |
| Stafylas, PC | 1 |
| Georgianos, PI | 1 |
| Saratzis, AN | 1 |
| Lasaridis, AN | 1 |
| Ye, S | 1 |
| Zheng, M | 2 |
| Hu, Y | 1 |
| Wu, F | 1 |
| Zhao, L | 1 |
| Chen, Y | 2 |
| Hu, YY | 1 |
| Ye, SD | 1 |
| Zhao, LL | 1 |
| Toblli, JE | 1 |
| Cao, G | 1 |
| Giani, JF | 1 |
| Angerosa, M | 1 |
| Dominici, FP | 1 |
| Gonzalez-Cadavid, NF | 1 |
| Xu, X | 2 |
| Chen, P | 2 |
| Zheng, Q | 2 |
| Chen, W | 2 |
| Ueda, Y | 1 |
| Morikawa, A | 1 |
| Ishizeki, K | 1 |
| Iwashima, Y | 1 |
| Muto, E | 1 |
| Oshima, E | 1 |
| Sekiguchi, M | 1 |
| Miura, T | 1 |
| Itoh, H | 1 |
| Haneda, M | 2 |
| Hempe, J | 1 |
| Elvert, R | 1 |
| Schmidts, HL | 1 |
| Kramer, W | 1 |
| Herling, AW | 1 |
| Elrashidy, RA | 2 |
| Asker, ME | 2 |
| Mohamed, HE | 2 |
| Hu, W | 1 |
| Yu, Q | 1 |
| Zhang, J | 2 |
| Liu, D | 1 |
| Tawfik, MK | 2 |
| Somogyi, A | 1 |
| Chen, J | 1 |
| Masoad, RE | 1 |
| Ewais, MM | 1 |
| Abd El-All, HS | 1 |
| Saad, S | 1 |
| Yong, R | 1 |
| Yaghobian, D | 1 |
| Wong, MG | 1 |
| Kelly, DJ | 1 |
| Chen, XM | 2 |
| Pollock, CA | 2 |
| Fritsche, L | 1 |
| Budde, K | 1 |
| Glander, P | 1 |
| Einecke, G | 1 |
| Diekmann, F | 1 |
| Schötschel, R | 1 |
| Neumayer, HH | 1 |
| Panchapakesan, U | 1 |
| Tanimoto, M | 1 |
| Fan, Q | 1 |
| Gohda, T | 1 |
| Shike, T | 1 |
| Makita, Y | 1 |
| Tomino, Y | 1 |
| Agarwal, R | 3 |
| Saha, C | 1 |
| Battiwala, M | 1 |
| Vasavada, N | 1 |
| Curley, T | 1 |
| Chase, SD | 1 |
| Sachs, N | 1 |
| Semret, MH | 1 |
| Katavetin, P | 1 |
| Eiam-Ong, S | 1 |
| Suwanwalaikorn, S | 1 |
| Rodriguez, WE | 1 |
| Tyagi, N | 1 |
| Joshua, IG | 1 |
| Passmore, JC | 1 |
| Fleming, JT | 1 |
| Falcone, JC | 1 |
| Tyagi, SC | 1 |
| Okada, T | 1 |
| Wada, J | 2 |
| Hida, K | 1 |
| Eguchi, J | 1 |
| Hashimoto, I | 1 |
| Baba, M | 1 |
| Yasuhara, A | 1 |
| Shikata, K | 3 |
| Makino, H | 3 |
| Bakris, GL | 1 |
| Miyamoto, Y | 1 |
| Sawai, K | 1 |
| Mori, K | 1 |
| Mukoyama, M | 1 |
| Nakao, K | 1 |
| Yoshimasa, Y | 1 |
| Suga, S | 1 |
| Ohga, S | 1 |
| Yozai, K | 1 |
| Okada, S | 1 |
| Ogawa, D | 1 |
| Usui, H | 1 |
| Shikata, Y | 1 |
| Lee, MY | 1 |
| Lee, EY | 1 |
| Lee, BJ | 1 |
| Won, CS | 1 |
| Koh, JH | 1 |
| Shin, JY | 1 |
| Shin, YG | 1 |
| Cho, BP | 1 |
| Chung, CH | 1 |
| Jin, HM | 1 |
| Pan, Y | 1 |
| Ohtomo, S | 1 |
| Izuhara, Y | 1 |
| Takizawa, S | 1 |
| Yamada, N | 1 |
| Kakuta, T | 1 |
| Schneider, CA | 1 |
| Ferrannini, E | 1 |
| Defronzo, R | 1 |
| Schernthaner, G | 1 |
| Yates, J | 1 |
| Erdmann, E | 1 |
| Ogawa, S | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Ishizuka, T | 1 |
| Ito, S | 1 |
| Kaizu, K | 1 |
| Ko, GJ | 1 |
| Kang, YS | 1 |
| Han, SY | 1 |
| Lee, MH | 1 |
| Song, HK | 1 |
| Han, KH | 1 |
| Kim, HK | 1 |
| Han, JY | 1 |
| Cha, DR | 1 |
| Yoshimoto, T | 1 |
| Naruse, M | 1 |
| Nishikawa, M | 1 |
| Naruse, K | 1 |
| Tanabe, A | 1 |
| Seki, T | 1 |
| Imaki, T | 1 |
| Demura, R | 1 |
| Aikawa, E | 1 |
| Demura, H | 1 |
| Koya, D | 1 |
| Kikkawa, R | 1 |
| Ushiyama, C | 1 |
| Osada, S | 1 |
| Hara, M | 1 |
| Shimada, N | 1 |
| Koide, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®[NCT01043029] | Phase 2 | 302 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for pioglitazone and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Chemoprevention; Diabetes Mellitus, Type 2; | 2020 |
Pathophysiology of Diabetic Dyslipidemia.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicrons; Diabetes | 2018 |
Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.
Topics: Albuminuria; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; | 2010 |
[Thiazolidinediones].
Topics: Animals; Diabetic Nephropathies; Humans; Pioglitazone; Thiazolidinediones | 2010 |
[Oral antidiabetic drugs in chronic renal disease].
Topics: Administration, Oral; Blood Glucose; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dis | 2012 |
Treating type 2 diabetes in renal insufficiency: the role of pioglitazone.
Topics: Area Under Curve; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Li | 2003 |
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; E | 2006 |
[Microinflammation in the pathogenesis of diabetic nephropathy].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Diabetic Nephropathies; | 2007 |
16 trials available for pioglitazone and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combina | 2017 |
Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, | 2018 |
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; | 2014 |
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-P | 2015 |
Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cytokines; Diabetes Mellitus, Type 2; | 2009 |
Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glyc | 2008 |
Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dr | 2010 |
Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2011 |
A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glipizide; Humans; Hypoglycemic Age | 2005 |
Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-R | 2006 |
Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications.
Topics: Aged; Biomarkers; Blood Urea Nitrogen; Chromatography, High Pressure Liquid; Contrast Media; Creatin | 2007 |
Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Com | 2007 |
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Femal | 2008 |
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch | 2008 |
Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.
Topics: Albuminuria; Blood Glucose; Cytoskeletal Proteins; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2001 |
38 other studies available for pioglitazone and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
The efficacy of pioglitazone for renal protection in diabetic kidney disease.
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration | 2022 |
Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Diabetes Mellit | 2020 |
Renoprotective effect of pioglitazone by the prevention of glomerular hyperfiltration through the possible restoration of altered macula densa signaling in rats with type 2 diabetic nephropathy.
Topics: Animals; Cyclooxygenase 2; Desmin; Diabetic Nephropathies; Juxtaglomerular Apparatus; Kidney Glomeru | 2012 |
Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.
Topics: Administration, Intravenous; Animals; Biological Availability; Blood Glucose; Diabetes Mellitus, Exp | 2015 |
Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36).
Topics: Aged; Albuminuria; Blood Glucose; Cardiovascular Diseases; Cause of Death; Cohort Studies; Diabetes | 2015 |
An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Evaluation, Preclinical; Humans; Hy | 2015 |
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2016 |
Effects of vitamin D combined with pioglitazone hydrochloride on bone mineral density and bone metabolism in Type 2 diabetic nephropathy.
Topics: Absorptiometry, Photon; Adult; Aged; Analysis of Variance; Biomarkers; Body Mass Index; Body Weights | 2017 |
Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease.
Topics: Animals; Computational Biology; Diabetic Nephropathies; Diabetic Neuropathies; Gene Expression Profi | 2017 |
Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Blood Glucose; Cholesterol; Cystatin C; Cystatins; Diabetic Ne | 2008 |
Translation of basic science into clinical medicine: novel targets for diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomedical Research; Clinical Medicine; Diabetic N | 2009 |
Rosiglitazone and pioglitazone. Beware macular oedema.
Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular E | 2009 |
Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2010 |
Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics.
Topics: Adult; Aged; Chemokine CCL2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hem | 2010 |
Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis.
Topics: Animals; Antifibrinolytic Agents; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dos | 2011 |
Effect of pioglitazone on diabetic nephropathy and expression of HIF-1α and VEGF in the renal tissues of type 2 diabetic rats.
Topics: Animals; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypoxia- | 2011 |
Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications.
Topics: Animals; Blood Chemical Analysis; Caloric Restriction; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2012 |
Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Di | 2012 |
Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.
Topics: Adipokines; Animals; Blood Glucose; Body Weight; Chemokines; Connective Tissue Growth Factor; Diabet | 2012 |
Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy.
Topics: Amides; Animals; Antihypertensive Agents; Cardiomyopathies; Diabetic Nephropathies; Disease Models, | 2012 |
Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Catalase | 2012 |
Pioglitazone, extract of compound Danshen dripping pill, and quercetin ameliorate diabetic nephropathy in diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herba | 2013 |
Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents | 2012 |
Role of the EGF receptor in PPARγ-mediated sodium and water transport in human proximal tubule cells.
Topics: Animals; Aquaporin 1; Cells, Cultured; Diabetic Nephropathies; ErbB Receptors; Female; Gene Expressi | 2013 |
The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells.
Topics: Cell Line; Cell Survival; Chemokine CCL2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Diabetic N | 2004 |
Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.
Topics: Albuminuria; Animals; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic | 2004 |
Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy.
Topics: Anti-Inflammatory Agents; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hyp | 2006 |
Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus.
Topics: Animals; Arterioles; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diab | 2006 |
Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Topics: Albuminuria; Animals; Blotting, Western; Body Weight; Cell Cycle; Cell Line; Collagen Type IV; Cycli | 2006 |
Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2006 |
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Cells, Cultured; Collagen Type IV; Diabetes Mellitus, E | 2007 |
Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Age | 2007 |
[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Th | 2007 |
Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glycation End Pr | 2007 |
Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Blood Glucose; Blood Pressure; | 2008 |
Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Topics: Animals; Cells, Cultured; Chemokine CCL2; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Neph | 2008 |
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Dia | 1997 |
Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diacylglycerol Kinase; Disease | 2001 |